Where can I find news about FSGS?

The latest press releases, SEC filings, and earnings call transcripts for First Trust SMID Growth Strength ETF (FSGS) are listed on this page. Press releases come from the company's investor relations feed; filings come directly from SEC EDGAR.

Where are FSGS's SEC filings?

First Trust SMID Growth Strength ETF (FSGS)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.

When was FSGS's last earnings call?

The most recent earnings call transcript for First Trust SMID Growth Strength ETF (FSGS) is on this page with the full speaker-by-speaker conversation. Older quarter transcripts are also available — click any past quarter pill to load it.

FSGS

First Trust SMID Growth Strength ETF

NASDAQ·Asset Management · Financial Services

$31.62$0.24+0.75%

Market cap$30.03M·Jul 24 1:39 PM UTC

Press Releases

Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib
HONG KONG, July 8, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced the closing of its previously announced exclusive licensing and collaborat
gurufocus.comJul 8, 2026 · 1:00 AM
Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion
HONG KONG, June 4, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreemen
gurufocus.comJun 4, 2026 · 12:00 AM
Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines f
gurufocus.comJun 2, 2026 · 8:00 AM

SEC Filings

No recent filings indexed.

Transcripts

PRO

Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.

Click below to see what's inside, then upgrade to read every transcript for FSGS and 80,000+ other tickers.

Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.

Frequently Asked Questions About FSGS

Where can I find news about FSGS?: The latest press releases, SEC filings, and earnings call transcripts for First Trust SMID Growth Strength ETF (FSGS) are listed on this page. Press releases come from the company's investor relations feed; filings come directly from SEC EDGAR.
Where are FSGS's SEC filings?: First Trust SMID Growth Strength ETF (FSGS)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.
When was FSGS's last earnings call?: The most recent earnings call transcript for First Trust SMID Growth Strength ETF (FSGS) is on this page with the full speaker-by-speaker conversation. Older quarter transcripts are also available — click any past quarter pill to load it.

First Trust SMID Growth Strength ETF

Frequently Asked Questions About FSGS

First Trust SMID Growth Strength ETF

Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib

Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion

Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases

Frequently Asked Questions About FSGS

Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib

Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion

Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases